Insitro outsources clinical costs to pharma

Partnering lets insitro sell discovery work without taking on the most capital intensive part of drug development. In this model, insitro uses its lab, data, and machine learning systems to find targets and early programs, then a large pharma partner picks up the far larger bill for human trials, regulatory filings, and global launch. That keeps insitro’s cash burn centered on repeatable research infrastructure instead of multi year Phase I to III trials.1 2 3 4

• The AstraZeneca deal is a clean example. insitro gets $40 million upfront, can earn about $1.46B in downstream milestones, plus royalties, while AstraZeneca leads clinical development, regulatory work, and commercialization. insitro keeps upside if a drug works, but avoids funding late stage trials itself.1 2
• The Bristol Myers Squibb relationship shows how this can compound. BMS selected an initial ALS target in December 2024, insitro received $25 million for discovery milestones tied to that work, and by March 2026 BMS had expanded the collaboration to two more ALS targets.3 4
• This is different from an owned pipeline model, where the biotech pays to move its own drug through the clinic. Partnered AI drug discovery companies can run more shots on goal, because each successful handoff recycles partner capital back into the discovery engine instead of tying it up in one expensive trial program.4 5

Going forward, the winners in this category are likely to be the companies that can repeatedly hand pharma partners new targets, not just prove they can do it once. If insitro keeps converting platform work into additional target picks and expanded scopes, partnering can scale its revenue base while leaving the largest development checks to AstraZeneca, BMS, and other big drug makers.1 3 4 5